Biodesix (BDSX) Registration Filing summary

Company overview and business model

• Focuses on diagnostic solutions for lung disease, using a multi-omic approach to provide personalized clinical insights and improve patient outcomes.

• Offers five commercialized blood-based lung cancer tests and over 30 assays for clinical and research use, serving more than 65 biopharmaceutical customers and academic partners.

• Provides services to biopharmaceutical companies, including diagnostic research, clinical trial testing, and companion diagnostics development.

• Utilizes genomics, transcriptomics, proteomics, radiomics, and AI-enabled informatics to develop innovative diagnostic tests.

Financial performance and metrics

• As of September 30, 2024, had $31.4 million in cash and cash equivalents and $40.0 million in principal balance outstanding on a senior secured term loan facility.

• Net tangible book value as of September 30, 2024, was $27.9 million, or $0.19 per share.

• After a $50 million offering at $1.66 per share, adjusted net tangible book value would be $76.2 million, or $0.43 per share, with immediate dilution of $1.23 per share to new investors.

• Has incurred significant losses since inception and continues to operate at a loss, with a going concern statement included in recent financials.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• Additional uses include commercial expansion, supporting product pipeline and R&D, and funding technology integration and automation.

• Management retains broad discretion over allocation and timing of expenditures.